{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:12:34Z","timestamp":1772849554953,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jiac.2024.102596","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T22:55:33Z","timestamp":1734735333000},"page":"102596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-tuberculous mycobacterial shoulder arthritis with acute exacerbation soon after initiation of immune checkpoint inhibitor: A case report"],"prefix":"10.1016","volume":"31","author":[{"given":"Shugo","family":"Inada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihito","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-463X","authenticated-orcid":false,"given":"Norifumi","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ohge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.102596_bib1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jiac.2024.102596_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2024.102596_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2024.102596_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02512-2021","article-title":"The paradox of immune checkpoint inhibition re-activating tuberculosis","volume":"60","author":"Ahmed","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2024.102596_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000866","article-title":"Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors","volume":"5","author":"Anand","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jiac.2024.102596_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1183\/23120541.00364-2022","article-title":"Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review","volume":"8","author":"Lombardi","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jiac.2024.102596_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-023-08537-w","article-title":"Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?","volume":"23","author":"Azzar\u00e0","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2024.102596_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972302","article-title":"Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis","volume":"13","author":"Pang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2024.102596_bib9","doi-asserted-by":"crossref","first-page":"ofz108","DOI":"10.1093\/ofid\/ofz108","article-title":"Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease","volume":"6","author":"Asakura","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2024.102596_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00250-2019","article-title":"Non-tuberculous mycobacterial pulmonary disease","volume":"54","author":"Cowman","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2024.102596_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cam4.4393","article-title":"Infectious complications of immune checkpoint inhibitors in solid organ malignancies","volume":"11","author":"Ross","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.jiac.2024.102596_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jiac.2024.102596_bib13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2024.102596_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/ijms23031619","article-title":"PD-L1 expression in monocytes correlates with bacterial burden and treatment outcomes in active pulmonary tuberculosis","volume":"23","author":"Pan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiac.2024.102596_bib15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/jcm8050736","article-title":"The clinical significance of programmed death-1, regulatory T cells and myeloid derived suppressor cells in patients with nontuberculous mycobacteria-lung disease","volume":"8","author":"Shu","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jiac.2024.102596_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep42004","article-title":"Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2024.102596_bib17","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jiac.2024.102596_bib18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1\u2013Mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jiac.2024.102596_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.jiac.2024.102596_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiac.2024.102596_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1473-3099(05)70140-7","article-title":"Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals","volume":"5","author":"Lawn","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2024.102596_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","article-title":"Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2024.102596_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1586\/eri.11.21","article-title":"Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy","volume":"9","author":"Lawn","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jiac.2024.102596_bib24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.102596_bib25","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jiac.2024.102596_bib26","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.932924","article-title":"Re-challenging with nivolumab in metastatic renal cell carcinoma after immune-related interstitial pneumonia: a Case report","volume":"22","author":"Shibata","year":"2021","journal-title":"Am J Case Rep"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2400343X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X2400343X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:01:37Z","timestamp":1741280497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X2400343X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1341321X2400343X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.102596","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-tuberculous mycobacterial shoulder arthritis with acute exacerbation soon after initiation of immune checkpoint inhibitor: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.102596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102596"}}